X0306 4 2018-11-14 0 0001325879 AVEO PHARMACEUTICALS INC AVEO 0001239241 EVNIN ANTHONY B C/O AVEO PHARMACEUTICALS, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2018-11-14 4 S 0 325139 1.9003 D 821929 I By Funds Common Stock 2018-11-15 4 S 0 670894 1.8606 D 151035 I By Funds Common Stock 2018-11-16 4 S 0 151035 1.8168 D 0 I By Funds Common Stock 418414 D Consists of (a) 58,519 shares of common stock sold by Venrock Associates, or VA, (b) 260,087 shares of common stock sold by Venrock Associates III, L.P., or VA III, (c) 6,502 shares of common stock sold by Venrock Entrepreneurs Fund III, L.P., or VEF III, and (d) 31 shares of common stock sold by VEF Management III, LLC, or VEFM III. The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.89 to $1.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Dr. Evnin is a General Partner of VA. Venrock Management III, LLC, or VM III, is the sole General Partner of VA III. VEFM III, is the sole General Partner of VEF III. Dr. Evnin is a Member of VM III and VEFM III. Dr. Evnin expressly disclaims beneficial ownership over all shares held by or on behalf of VA, VA III, VEF III, VM III, and VEFM III, except to the extent of his indirect pecuniary interest therein. Consists of (a) 120,749 shares of common stock sold by VA, (b) 536,665 shares of common stock sold by VA III, (c) 13,416 shares of common stock sold by VEF III, and (d) 64 shares of common stock sold by VEFM III. The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.85 to $1.875, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Consists of (a) 27,184 shares of common stock sold by VA, (b) 120,817 shares of common stock sold by VA III, (c) 3,020 shares of common stock sold by VEF III, and (d) 14 shares of common stock sold by VEFM III. The price reported is a weighted average price. The shares were sold in multiple transactions at pricing ranging from $1.785 to $1.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. None of the shares held directly by Dr. Evnin were sold in these transactions. /s/ Karuna Rubin, attorney-in-fact 2018-11-16